2种疗效判断标准对洛索洛芬治疗类风湿关节炎的评价

Efficacy of loxoprofen for rheumatoid arthritis using two evaluation standards

目的 :国内、美国风湿病学会 (ACR) 2种疗效判断标准评价洛索洛芬 (loxoprofen)治疗类风湿关节炎 (RA)的疗效及不良反应。方法 :选择 5 0例 ,年龄 (4 8±s 13)a ,4 0～ 69aRA活动期病人 (男女不限 ) ,口服洛索洛芬 60mg ,tid× 4wk ,比较用药前后关节压痛数、关节肿胀数、血沉、C反应蛋白等临床及实验室指标的变化 ,用国内、ACR不同疗效判断标准评价洛索洛芬治疗RA的疗效及不良反应。结果 :洛索洛芬治疗RA的总有效率达 74 %(国内标准 )和 80 % (ACR标准 ) ,2种疗效判断标准无显著差异 ,各项临床及实验室指标均有显著改善 ,不良反应发生率 10 % ,未出现危及生命的不良反应。结论 :洛索洛芬治疗RA安全。

AIM: To evaluate the efficacy and adverse reaction of loxoprofen in treatment of rheumatoid arthritis(RA) by internal and international standards. METHODS: Fifty patients (48± s 13)a, 40 69 a with RA were orally given loxoprofen 60 mg, tid, for 4 wk after the food. Before and after treatment, clinical and experimental indexes, such as tenderness and swelling index of joint, ESR, and CRP were detected. The efficacy and adverse reactions were evaluated by two different standards established by American College of Rheumatology (ACR) and Chinese Rheumatology Association (CRA), respectively. RESULTS: The total effective rate of loxoprofen for RA was 74% (CRA) or 80%(ACR). There was no significant difference between the results evaluated by the two different standards for efficacy of loxoprofen on RA. Every clinical or experimental index was improved significantly ( P <0.01) . The rate of adverse reactoins was 10%, and no serious or vital adverse reaction appeared. CONCLUSION: Loxoprofen is an effective and safe drug in the treatment of rheumatoid arthritis.